Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies

References

• Roda D , CervantesA. Biomarkers in colorectal cancer: the future is getting closer. Clin. Transl. Oncol.12(4), 241–242 (2010).
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare . Cancer in Australia: actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012. Asia Pac. J. Clin. Oncol.9(3), 199–213 (2013).
   PubMed Web of Science ®Google Scholar
• Peeters M , PriceT. Biologic therapies in the metastatic colorectal cancer treatment continuum – applying current evidence to clinical practice. Cancer Treat. Rev.38(5), 397–406 (2012).
   PubMed Web of Science ®Google Scholar
• Herbst RS . Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys.59(2 Suppl.), 21–26 (2004).
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A , MartiniM, MolinariFet al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res.69(5), 1851–1857 (2009).
   PubMed Web of Science ®Google Scholar
• Citri A , YardenY. EGF–ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol.7(7), 505–516 (2006).
   PubMed Web of Science ®Google Scholar
• Amado RG , WolfM, PeetersMet al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Karapetis CS , Khambata-FordS, JonkerDJet al. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Lievre A , BachetJB, LeCorre Det al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8), 3992–3995 (2006).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, MakhsonAet al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.27(5), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KohneCH, LangIet al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer. updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Peeters M , DouillardJY, Van CutsemEet al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol.31(6), 759–765 (2013).
   PubMed Web of Science ®Google Scholar
• Douillard JY , OlinerKS, SienaS. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med.369(11), 1023–1034 (2013).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F , MartiniM, MolinariFet al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol.26(35), 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Roth AD , TejparS, DelorenziMet al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer. Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J. Clin. Oncol.28(3), 466–474 (2010).
   PubMed Web of Science ®Google Scholar
• Price TJ , HardinghamJE, LeeCKet al. Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J. Clin. Oncol.29(19), 2675–2682 (2011).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneC-H, HitreEet al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14), 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Cunningham D , HumbletY, SienaSet al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Sobrero AF , MaurelJ, FehrenbacherLet al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol.26(14), 2311–2319 (2008).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , NowackiM, LangIet al. Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC). The CRYSTAL trial. J. Clin. Oncol.25(Suppl. 18), 4000 (2007).
   Google Scholar
• Saltz LB , MeropolNJ, LoehrerPJSr, NeedleMN, KopitJ, MayerRJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Jonker DJ , O’CallaghanCJ, KarapetisCSet al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.357(20), 2040–2048 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , PeetersM, SienaSet al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25(13), 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Price T, Peeters M, Kim TW et al. ASPECCT: a randomized, multicenter, open-label, Phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Presented at: European Cancer Congress 2013. Amsterdam, The Netherlands, 27 September–October 1 2013 (Abstract LBA18).
   Google Scholar
• Peeters M , PriceTJ, CervantesAet al. Final results from a randomized Phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann. Oncol.25(1), 107–116 (2014).
   PubMed Web of Science ®Google Scholar
• Seymour MT , BrownSR, MiddletonGet al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO). A prospectively stratified randomised trial. Lancet Oncol.14(8), 749–759 (2013).
   PubMed Web of Science ®Google Scholar
• Hecht JR , MitchellE, ChidiacTet al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27(5), 672–680 (2009).
   PubMed Web of Science ®Google Scholar
• Chung CH , MirakhurB, ChanEet al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med.358(11), 1109–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Kimura H , SakaiK, AraoT, ShimoyamaT, TamuraT, NishioK. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci.98(8), 1275–1280 (2007).
   PubMed Web of Science ®Google Scholar
• Schneider-Merck T , LammertsVan Bueren JJ, BergerSet al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol.184(1), 512–520 (2010).
   PubMed Web of Science ®Google Scholar
• Hocking CM , TownsendAR, PriceTJ. Panitumumab in metastatic colorectal cancer. Expert Rev. Anticancer Ther.13(7), 781–793 (2013).
   PubMed Web of Science ®Google Scholar
• Ciardiello F , BiancoR, DamianoVet al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res.5(4), 909–916 (1999).
   PubMed Web of Science ®Google Scholar
• Maughan TS , AdamsRA, SmithCG. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer. Results of the randomised Phase 3 MRC COIN trial. Lancet377(9783), 2103–2114 (2011).
   PubMed Web of Science ®Google Scholar
• Tveit KM , GurenT, GlimeliusBet al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol.30(15), 1755–1762 (2012).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML , LafleurB, LevyDEet al. Randomized Phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol.23(36), 9265–9274 (2005).
   PubMed Web of Science ®Google Scholar
• Townsley CA , MajorP, SiuLLet al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br. J. Cancer94(8), 1136–1143 (2006).
   PubMed Web of Science ®Google Scholar
• Kuo T , ChoCD, HalseyJet al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol.23(24), 5613–5619 (2005).
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ , PriceTJ, ChongGet al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib. preclinical evaluation and results of the Phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J. Clin. Oncol.30(13), 1505–1512 (2012).
   PubMed Web of Science ®Google Scholar
• Schubbert S , ShannonK, BollagG. Hyperactive RAS in developmental disorders and cancer. Nat. Rev. Cancer7(4), 295–308 (2007).
   PubMed Web of Science ®Google Scholar
• Andreyev HJ , NormanAR, CunninghamDet al. Kirsten RAS mutations in patients with colorectal cancer. The ‘RASCAL II’ study. Br. J. Cancer85(5), 692–696 (2001).
   PubMed Web of Science ®Google Scholar
• Vaughn CP , ZobellSD, FurtadoLV, BakerCL, SamowitzWS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer50(5), 307–312 (2011).
   PubMed Web of Science ®Google Scholar
• Malumbres M , BarbacidM. RAS oncogenes: the first 30 years. Nat. Rev. Cancer3(6), 459–465 (2003).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB, BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11, 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Peeters M , OlinerKS, ParkerAet al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized Phase III study of metastatic colorectal cancer. Clin. Cancer Res.19(7), 1902–1912 (2013).
   PubMed Web of Science ®Google Scholar
• Young A , LouD, McCormickF. Oncogenic and wild-type RAS play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov.3(1), 112–123 (2013).
   PubMed Web of Science ®Google Scholar
• Adelstein BA , DobbinsTA, HarrisCA, MarschnerIC, WardRL. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur. J. Cancer47(9), 1343–1354 (2011).
   PubMed Web of Science ®Google Scholar
• Tol J , KoopmanM, CatsAet al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med.360(6), 563–572 (2009).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, HartmannJTet al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol.22(7), 1535–1546 (2011).
   PubMed Web of Science ®Google Scholar
• Douillard JY , SienaS, CassidyJet al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol.28(31), 4697–4705 (2010).
   PubMed Web of Science ®Google Scholar
• Mao C , HuangYF, YangZY, ZhengDY, ChenJZ, TangJL. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer. Cancer119(4), 714–721 (2013).
   PubMed Web of Science ®Google Scholar
• Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer (CRC) with either KRAS WT or G13D mutation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000901808
   Google Scholar
• Safaee Ardekani G , JafarnejadSM, TanL, SaeediA, LiG. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE7(10), e47054 (2012).
   PubMed Web of Science ®Google Scholar
• Tol J , NagtegaalID, PuntCJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med.361(1), 98–99 (2009).
   PubMed Web of Science ®Google Scholar
• Saridaki Z , TzardiM, SfakianakiMet al. BRAF V600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice. correlations with clinical characteristics, and its impact on patients’ outcome. PLoS ONE8(12), e84604 (2013).
   PubMed Web of Science ®Google Scholar
• Wong R , CunninghamD. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J. Clin. Oncol.26(35), 5668–5670 (2008).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , CutsemEV, RougierPet al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer. Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer48(10), 1466–1475 (2012).
   PubMed Web of Science ®Google Scholar
• Hynes NE , LaneHA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer5(5), 341–354 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou XP , LoukolaA, SalovaaraRet al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am. J. Pathol.161(2), 439–447 (2002).
   PubMed Web of Science ®Google Scholar
• Nassif NT , LoboGP, WuXet al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene23(2), 617–628 (2004).
   PubMed Web of Science ®Google Scholar
• Jhawer M , GoelS, WilsonAJet al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res.68(6), 1953–1961 (2008).
   PubMed Web of Science ®Google Scholar
• Frattini M , SalettiP, RomagnaniEet al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer97(8), 1139–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Price TJ , HardinghamJE, LeeCKet al. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Med.2(3), 277–285 (2013).
   PubMed Web of Science ®Google Scholar
• Yarden Y . The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur. J. Cancer37(Suppl. 4), S3–S8 (2001).
   PubMed Web of Science ®Google Scholar
• Nagata Y , LanKH, ZhouXet al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell6(2), 117–127 (2004).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK , WangMY, VivancoIet al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Ogino S , NoshoK, KirknerGJet al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol.27(9), 1477–1484 (2009).
   PubMed Web of Science ®Google Scholar
• Wilson PM , LabonteMJ, LenzHJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J.16(3), 262–272 (2010).
   PubMed Web of Science ®Google Scholar
• Bardelli A , SienaS. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol.28(7), 1254–1261 (2010).
   PubMed Web of Science ®Google Scholar
• Souglakos J , PhilipsJ, WangRet al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer101(3), 465–472 (2009).
   PubMed Web of Science ®Google Scholar
• Prenen H , DeSchutter J, JacobsBet al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res.15(9), 3184–3188 (2009).
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A , DiNicolantonio F, NichelattiMet al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE4(10), 1–9 (2009).
   Web of Science ®Google Scholar
• Moroni M , Sartore-BianchiA, BenvenutiS, ArtaleS, BardelliA, SienaS. Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Ann. Oncol.16(11), 1848–1849 (2005).
   PubMed Web of Science ®Google Scholar
• Custodio A , FeliuJ. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit. Rev. Oncol. Hematol.85(1), 45–81 (2013).
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A , FieuwsS, VeroneseSet al. Standardisation of EGFR FISH in colorectal cancer. Results of an international interlaboratory reproducibility ring study. J. Clin. Pathol.65(3), 218–223 (2012).
   PubMed Web of Science ®Google Scholar
• Moroni M , VeroneseS, BenvenutiSet al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol.6(5), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Jiang Z , LiC, LiF, WangX. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS ONE8(2), e56205 (2013).
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ , LinardouH, KosmidisP, BafaloukosD, MurrayS. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann. Oncol.22(3), 545–552 (2011).
   PubMed Web of Science ®Google Scholar
• Yang ZY , ShenWX, HuXFet al. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis. J. Hematol. Oncol.5, 52–57 (2012).
   PubMed Web of Science ®Google Scholar
• Jacobs B , DeRoock W, PiessevauxHet al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol.27(30), 5068–5074 (2009).
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G , KotoulaV, DeRoock Wet al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer. Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer13(1), 49 (2013).
   PubMed Web of Science ®Google Scholar
• Jonker DJ , KarapetisCS, HarbisonCet al. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br. J. Cancer110(3), 648–655 (2013).
   PubMed Web of Science ®Google Scholar